ConductScience.org, home

Paper · 36551663

References149

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118259690The epidermal growth factor receptor family: biology driving targeted therapeutics.Cell Mol Life Sci2008https://conductscience.org/library/papers/18259690PubMed
229383036Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.Ther Adv Med Oncol2018https://conductscience.org/library/papers/29383036PubMed
332847130Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.Cancers (Basel)2020https://conductscience.org/library/papers/32847130PubMed
425891541Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.Lung Cancer2015https://conductscience.org/library/papers/25891541PubMed
531548545Breast cancer.Nat Rev Dis Primers2019https://conductscience.org/library/papers/31548545PubMed
635625959Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer.Cancers (Basel)2022https://conductscience.org/library/papers/35625959PubMed
714623113Shc-dependent pathway is redundant but dominant in MAPK cascade activation by EGF receptors: a modeling inference.FEBS Lett2003https://conductscience.org/library/papers/14623113PubMed
824300455HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome.Eur J Cancer2014https://conductscience.org/library/papers/24300455PubMed
926689995Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.Oncotarget2016https://conductscience.org/library/papers/26689995PubMed
1032034073Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.Clin Cancer Res2020https://conductscience.org/library/papers/32034073PubMed
1132080212Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers.Sci Rep2020https://conductscience.org/library/papers/32080212PubMed
1230975923Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.Oncologist2019https://conductscience.org/library/papers/30975923PubMed
1335839938Targeting HER3-dependent activation of nuclear AKT improves radiotherapy of non-small cell lung cancer.Radiother Oncol2022https://conductscience.org/library/papers/35839938PubMed
1434320350ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.Cell Rep2021https://conductscience.org/library/papers/34320350PubMed
1510880430The ErbB signaling network: receptor heterodimerization in development and cancer.EMBO J2000https://conductscience.org/library/papers/10880430PubMed
1634548309Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer.Cancer Discov2022https://conductscience.org/library/papers/34548309PubMed
1733750895Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer.Oncogene2021https://conductscience.org/library/papers/33750895PubMed
1831519989ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.Oncogene2020https://conductscience.org/library/papers/31519989PubMed
1924667376Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.Sci Signal2014https://conductscience.org/library/papers/24667376PubMed
2034084213HER3 expression and MEK activation in non-small-cell lung carcinoma.Lung Cancer Manag2021https://conductscience.org/library/papers/34084213PubMed

papers-2026-11-12-0.1.0

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/papers/v1/36551663/references